Table of Contents
Definition of Thalassemia
Thalassemia is a microcytic-hypochromic anemia. Its cause is a decreased synthesis of one or several globin chains. Since globin synthesis is flawed, the disease is one of the so-called hemoglobinopathies. Depending on which globin chain is affected by the disorder, one speaks of α- or ß-thalassemia.
Thalassemias are caused by gene mutations leading to decreased production of globin protein. Deletions of α-globin genes cause α-thalassemia. There are two α-globin genes closely linked on chromosome 16. There is a total of 4 alleles.
Epidemiology of Thalassemia
Since thalassemia more frequently occurs in the Mediterranean area, including Turkey, it is also referred to as ‘Mediterranean anemia.’ However, it can be found worldwide. It is estimated that ca. 3% of the world population carry at least one ß-thalassemia gene. In Germany, the most frequent form is heterozygous ß-thalassemia.
Etiology of Thalassemia
Thalassemia is inherited autosomal-codominantly. At heterozygosity, a milder form of the disease develops (minor thalassemia). At homozygosity, the severe form (major thalassemia) can be observed. Also, the so-called intermediate thalassemia exists as an intermediate form. The primary causes are genetic defects, which form the pathogenetic basis of the decreased synthesis of one of several polypeptide chains of the globin molecule.
In turn, this results in a decreased hemoglobinization of the erythroblasts. In the blood count, this condition can be observed as hypochromasia of the erythrocytes. Additionally, the globin chains, which continue being produced, aggregate and make for increased apoptosis of precursor cells via different pathophysiological mechanisms. This condition also leads to decreased lifespan of the erythrocytes in the peripheral blood.
The characteristics and severity of the disease depend on the number of genes deleted:
|Asymptomatic, with mild anemia|
|HgH Disease||–/-α||Intermediate to severe chronic anemia|
|Hydrops Fetalis||–/–||Pre- or neonatal lethality|
Anemia, but no change in % of Hb A, A2 or F (all of them need α-globin chains for their synthesis).
There are two types of mutations in the β-globin gene:
- β+ mutations – variable decreased expression;
- β0 mutations – absent expression.
This results in three different clinical syndromes:
|Thalassemia minor||β0/β or β+/β||Asymptomatic; mild anemia|
|Thalassemia intermedia||β0/β or β+/β+||Variable moderate anemia, requiring occasional transfusion|
|Thalassemia major a.k.a. Cooley´s anemia||β0/β0 or β+/β+||Severe, transfusion-dependent anemia|
Clinic of Thalassemia
Depending on the genetic defect, thalassemia shows a variable clinical picture.
Minor thalassemia usually does not show severe symptoms. Slight hepatosplenomegaly and possibly a recurrent jaundice in a mild form can be present. Also, target cells can be observed in the blood count.
In its more distinct form, that is major thalassemia, the disease can lead to bone deformations, and even fractures, due to the reactive expansion of erythropoiesis in the bone marrow. Because of the decreased, and often pathological erythrocytes, hypoxia becomes clinically relevant as growth disturbances and trophic skin changes show in child age.
There are two consequences of decreased α-globin production:
- Decreased hemoglobin synthesis, causing microcytic, hypochromic anemia;
- Quantitative imbalance between α- and β-globin proteins, resulting in the formation of insoluble β-globin (HbH) or γ-globin (Hb Barts) aggregates in the RBC. These RBCs are often cleared in the spleen and liver, worsening the anemia.
It is most common in patients of Southern Asian (–allele) and African (-α allele) descent.
- Signs and symptoms of anemia;
- Chronic hemolysis with variable jaundice and cholelithiasis (bilirubin stones);
- Extramedullary hematopoiesis with frontal bossing and hepatosplenomegaly.
- Anasarca (generalized edema) from high-output heart failure;
- Causes death in the prenatal period.
Similar to α-Thalassemia.
- AR disorder: Africans, Italians, Greeks;
- → RBC count: splicing defect for minor; nonsense mutation for major (stop codon).
β = normal
β+ = some
β0 = none
Note that HbA is decreased because β-globin chain synthesis is decreased. There is a corresponding increase in HbA2 and HbF.
Note that there is no synthesis of HbA.
β-Thalassemia major (Cooley’s anemia)
- Decreased Hgb, Hct and MCV;
- Variable RBC count;
- Hemoglobin electrophoresis varies depending on the severity of the disease, with decreased HbA, increased HbF (α2γ2) and increased HbA2 (α2δ2).
It causes severe transfusion dependent anemia that develops at a few months of age (as HbF declines). If adequately transfused, children will develop normally, but will develop secondary hemochromatosis and die of heart disease in their 20s. If not transfused, there is a stunted growth, bony changes and high-output heart failure with death in infancy.
Diagnosis of Thalassemia
The blood count of minor thalassemia shows microcytic, hypochromic erythrocytes. Since this is also the case with iron deficiency and this condition is more frequent in practice, one should consider minor thalassemia when confronted with a non-confirmed iron deficiency anemia. A blood smear with target cells and poikilocytosis provides additional certainty.
- Laboratory studies: decreased Hgb, Hct, MCV; increased RBC count, RDW; HbH on hemoglobin electrophoresis; iron studies normal.
At major thalassemia and intermediate thalassemia, hypochromasia and poikilocytosis are more distinct. Reticulocytes, LDH and bilirubin are increased; haptoglobin is decreased.
Further criteria confirming the suspicion are a positive family history, disturbed hemoglobinization in bone marrow aspirate and genome analysis.
Therapy of Thalassemia
The ideal therapy is allogenic stem cell transplantation. Since the minor form does not usually require treatment, this primarily applies to major thalassemia.
Course and Prognosis of Thalassemia
If the anemia is not treated adequately, there is a massive expansion of hemopoiesis within the bone marrow. This can lead to a “hair on end” appearance on skull X-ray. If regular transfusions are given, iron chelation must be started.
While minor thalassemia and intermediate thalassemia mostly progress without complications, major thalassemia leads to death at infant age without treatment. Another life-shortening factor is increased iron residue in the organism (hemosiderosis). This is why therapeutic iron substitution of any kind is contraindicated.